Quetiapine
- Generic Name
- Quetiapine
- Brand Names
- Seroquel
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3O2S
- CAS Number
- 111974-69-7
- Unique Ingredient Identifier
- BGL0JSY5SI
- Background
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as Clozapine and Olanzapine.
- Indication
Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.
Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.
- Associated Conditions
- Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 389
- Registration Number
- NCT04521478
- Locations
- 🇺🇸
CT Clinical Research, Cromwell, Connecticut, United States
🇺🇸Institute of Living, Hartford, Connecticut, United States
🇺🇸Gulf Coast Clinical Research Center, Fort Myers, Florida, United States
Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium
- Conditions
- Covid19Pneumonia, ViralHyperactive Delirium
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- University of Miami
- Registration Number
- NCT04513314
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 757
- Registration Number
- NCT04513912
- Locations
- 🇵🇱
Centrum Badan Klinicznych PI House sp z o o, Gdansk, Poland
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸SW Biomedical Research LLC, Tucson, Arizona, United States
Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 350
- Registration Number
- NCT04446234
- Locations
- 🇨🇳
CHINA, Shanghai, Minhang, China
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
- Conditions
- Parkinson's Disease Psychosis
- Interventions
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 358
- Registration Number
- NCT04373317
- Locations
- 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States
🇺🇸Southern Arizona VA Health Care System, Tucson, AZ, Tucson, Arizona, United States
🇺🇸South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 676
- Registration Number
- NCT04338321
- Locations
- 🇧🇷
Ruschel Medicina e Pesquisa Clínica Ltda, Rio de Janeiro, Brazil
🇧🇷C J S Carvalho & Carvalho LTDA (Viver - Centro De Desospitalizacao Humana), Sao Paulo, Brazil
🇧🇷BR Trials, Sao Paulo, Brazil
Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Other: Standard of care meducations
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2023-05-09
- Target Recruit Count
- 28
- Registration Number
- NCT04280965
- Locations
- 🇺🇸
UT Health San Antonio, San Antonio, Texas, United States
Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine
- Conditions
- Parkinson's Disease
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT04164758
- Locations
- 🇺🇸
Movement Disorders Center of Arizona, Scottsdale, Arizona, United States
🇺🇸Tucson Neuroscience Research, Tucson, Arizona, United States
🇺🇸Galiz Research, Hialeah, Florida, United States
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2024-06-28
- Target Recruit Count
- 475
- Registration Number
- NCT04115319
- Locations
- 🇷🇴
Spitalul Clinic de Psihiatrie "Prof. Dr. Alexandru Obregia", Sectia Psihiatrie XII, Bucuresti, Romania
🇷🇺Saint Petersburg State Budgetary Institution of Healthcare "Psychoneurological Dispensay No 1", Saint Petersburg, Russian Federation
🇷🇺State Budgetary Institution of Healthcare of Stavropol territory "Regional Specialization Psychiatry Hospital # 2", Stavropol, Russian Federation
Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder
- Conditions
- Bipolar DisorderSchizophrenia
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2020-09-02
- Target Recruit Count
- 58
- Registration Number
- NCT03872596
- Locations
- 🇺🇸
Collaborative Neurosciences Network, LLC, Long Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.